Pfizer Or Gilead Sciences? Let’s Ask Peter Lynch

Summary:

  • Peter Lynch is often not considered a dividend investor, which is unfortunate.
  • He has so many valuable insights into dividend stocks that can benefit us. It’s just his success with 10-baggers has dominated the spotlights.
  • This article employs Lynch’s approach to evaluate Pfizer and Gilead Sciences.
  • My results show why Pfizer is the better dividend stock undercurrent conditions.
  • The article will also demonstrate the simplicity of Lynch’s method and the powerful insights they offer.
Tough Decisions Ahead written on desert road

gustavofrazao/iStock via Getty Images

Thesis

Many investors have benefited from Peter Lynch’s insights on growth stocks (the so-called 10-baggers). In contrast, his insights on dividend stocks are less known, which is an unfortunate waste in my view. In his writings, Lynch described his framework of dividing stocks into six categories. And


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.

We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme volatilities in BOTH the equity AND bond market.

Join for a 100% Risk-Free trial and see if our proven method can help you too.

Leave a Reply

Your email address will not be published. Required fields are marked *